Last reviewed · How we verify
NCT02983162
Is wGRS Associated With DD Recurrence?
trial in Dupuytren Contracture in 427 participants. Completed in 1 August 2018.
1 August 2018
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 427 |
| Start date | 10 March 2017 |
| Primary completion | 1 August 2018 |
| Estimated completion | 1 August 2018 |
| Sites | 1 location across Netherlands |
Conditions studied
- Dupuytren Contracture — all drugs for Dupuytren Contracture →
Sponsor
University Medical Center Groningen
Who can join
18 and older, any sex, with Dupuytren Contracture. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rationale: Retrospectively reviewing the participants of the GODDAF database, revealed a significant association between the weighted genetic risk score and Dupuytren disease recurrence. However, a significant dose-response relation was not found. This might be caused by underestimating the recurrence rate, due to the retrospective nature of determining recurrence. Therefore, we want to do a follow-up measurement of the GODDAF participants, to see whether they suffered from recurrent disease. Objective: We aim to determine whether the wGRS is associated with recurrent DD. Study design: An observational study, in which the participants of the GODDAF study are followed up. Study population: Patients affected by Dupuytren disease, aged 18-96 years, who were previously included in another study on the genetic basis of Dupuytren disease. Intervention (if applicable): NA Main study parameters/endpoints: The main study parameter is the presence of recurrent Dupuytren disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02983162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dupuytren Contracture
Currently open trials in the same condition.
- NCT06788847 — Evaluating Ultrasound-Guided Needle Knife for Dupuytren's Contracture · NA · recruiting
- NCT06806410 — The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery · Phase 4 · active not recruiting
- NCT04122313 — Post-contracture Release Radiation for Dupuytren's Disease · recruiting
- NCT03192020 — Trial Comparing Treatment Strategies in Dupuytren's Contracture · Phase 4 · active not recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02983162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 10 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02983162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing